An Evaluation of Kinerase Pro+Therapy Regimen Vs. Kinerase Vs. Control for the Treatment of Skin Aging

This study has been terminated.

First Received on June 25, 2007. Last Updated on December 18, 2007 History of Changes

Sponsor:	Innovative Medical
Information provided by:	Innovative Medical
ClinicalTrials.gov Identifier:	NCT00492479

Purpose

The purpose of this study is to compare the efficacy of the Kinerase Pro+Therapy regimen versus a single Kinerase product vs. control for the treatment of the signs of skin aging.

Condition	Intervention	Phase
Skin Aging	Drug: Kinerase Pro+Therapy Line day repair, serum, night repair Drug: Kinerase Pro+Therapy Line Ultra rich day repair Drug: LubriDerm	Phase IV

Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single Blind

Resource links provided by NLM:

MedlinePlus related topics: Skin Aging

Drug Information available for: LubriDerm

U.S. FDA Resources

Further study details as provided by Innovative Medical:

Study Start Date:	June 2007
Study Completion Date:	December 2007

Eligibility

Ages Eligible for Study:	35 Years to 55 Years
Genders Eligible for Study:	Female

Criteria

Inclusion Criteria:

Female patients 35-55 years of age with at least moderate signs of facial aging
Written informed consent
Likely to complete all study visits and follow study protocol

Exclusion Criteria:

Any dermatological or medical condition which would make patient participation unsafe or interfere with study outcomes or measurements
Known hypersensitivity to any study product or their components
Recent (within 4 weeks of baseline) surgical treatment to face (including IPL and other laser procedures)
Prior use of anti-aging treatments for 30 days prior to study entry (physician dispensed or prescribed treatments)
Planned facial procedures during the study (microdermabrasion, facials, etc)

o Botox and fillers cannot be used during the trial or for 3 months prior to study entry
Recent (within 60 days) or concurrent participation in another clinical trial
Concomitant topical or systemic therapy that my interfere with study measurements or outcomes
Use of any other topical photoaging/antiaging therapies during the study, other than the prescribed study regimens
Patients who are habitual tanners (outdoors or with tanning beds) who plan on tanning during the study
Wearing of cosmetics during study visits

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00492479

Locations

United States, California
Steve Yoelin MD practice
Santa Ana, California, United States, 92701

Sponsors and Collaborators

Innovative Medical

Investigators

Principal Investigator:

Steven Yoelin, MD

Private Practice

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00492479 History of Changes
Other Study ID Numbers:	5314
Study First Received:	June 25, 2007
Last Updated:	December 18, 2007
Health Authority:	United States: Institutional Review Board

ClinicalTrials.gov processed this record on February 12, 2012